Share Price and Basic Stock Data
Last Updated: December 12, 2025, 6:33 am
| PEG Ratio | 7.64 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Granules India Ltd operates in the competitive pharmaceuticals sector, focusing on both formulations and active pharmaceutical ingredients (APIs). As of March 2025, the company reported a revenue of ₹4,482 Cr, a slight decline from ₹4,506 Cr in the previous fiscal year. This stagnation in revenue growth can be attributed to various market pressures, including pricing pressures and regulatory challenges. On a quarterly basis, the latest figures show a modest recovery, with sales standing at ₹1,197 Cr in March 2025, indicating a consistent, albeit cautious, upward trend following a dip earlier in the year. The company’s sales have fluctuated notably over the past few quarters, peaking at ₹1,196 Cr in March 2023 but dropping to ₹986 Cr in June 2023 before rebounding. This volatility reflects the broader challenges faced by the pharmaceutical industry, including supply chain issues and shifting demand dynamics.
Profitability and Efficiency Metrics
Granules India has demonstrated resilience in maintaining profitability, with a net profit of ₹502 Cr for the fiscal year ending March 2025, translating to an earnings per share (EPS) of ₹20.68. The operating profit margin (OPM) for the same period stood at 21%, which appears strong when compared to industry peers, although it has seen fluctuations from a high of 26% in March 2021. The company has also recorded a return on equity (ROE) of 13.49%, which, while healthy, indicates that there is room for improvement in generating returns for shareholders. Efficiency metrics such as the cash conversion cycle (CCC) have lengthened to 207 days, suggesting potential challenges in working capital management. This extended CCC might raise concerns about liquidity and operational efficiency, especially in a sector where timely cash flow is critical.
Balance Sheet Strength and Financial Ratios
Granules India’s balance sheet reflects a mix of strengths and challenges. The company reported total borrowings of ₹1,807 Cr against reserves of ₹3,959 Cr, indicating a manageable debt-to-equity ratio of 0.34. This debt level is relatively low, which suggests that the company is not overly leveraged, providing it with a cushion to navigate market uncertainties. However, the interest coverage ratio (ICR) of 9.28x is a positive indicator, showcasing its ability to meet interest obligations comfortably. Despite this, the increase in depreciation expenses, which rose to ₹226 Cr as of March 2025, could pressure future profit margins. Moreover, the company’s current ratio of 1.56 indicates a healthy liquidity position, yet the quick ratio of 0.88 suggests potential challenges in meeting short-term liabilities without relying on inventory sales.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Granules India reveals a significant presence of institutional investors, with foreign institutional investors (FIIs) holding 14.09% and domestic institutional investors (DIIs) at 17.91%. This institutional backing can enhance investor confidence, suggesting a degree of endorsement from professional investors. However, it’s noteworthy that promoter holdings have gradually declined from 42.02% in December 2022 to 38.81% in September 2025. This reduction might raise eyebrows among retail investors regarding the promoters’ confidence in the company’s future. The number of shareholders has also decreased from 1,90,894 in December 2022 to 1,65,542 in September 2025, indicating a potential consolidation phase or exit by some retail investors, which could be a sign of waning enthusiasm.
Outlook, Risks, and Final Insight
The outlook for Granules India appears mixed. On one hand, the company has a solid foundation in the pharmaceuticals sector with a diverse product portfolio. On the other hand, it faces significant risks such as fluctuating sales, increasing competition, and potential regulatory hurdles. Investors might also be concerned about the sustainability of margins amid rising costs and pricing pressures. The company’s ability to innovate and adapt to changing market conditions will be crucial. Furthermore, the declining promoter shareholding could signal caution, prompting investors to closely monitor insider sentiment. Overall, while Granules India has strengths in its operational metrics and balance sheet, the challenges it faces require careful navigation, making it essential for investors to stay informed and consider both the potential upsides and risks before making investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Granules India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 141 Cr. | 112 | 239/84.3 | 31.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,246 Cr. | 390 | 479/192 | 87.9 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.8 Cr. | 29.9 | 31.0/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,461.38 Cr | 1,157.79 | 51.81 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,020 | 1,151 | 1,146 | 1,196 | 986 | 1,189 | 1,156 | 1,176 | 1,180 | 967 | 1,138 | 1,197 | 1,210 |
| Expenses | 808 | 908 | 915 | 967 | 849 | 977 | 905 | 920 | 921 | 763 | 907 | 945 | 963 |
| Operating Profit | 212 | 243 | 231 | 228 | 137 | 213 | 250 | 256 | 259 | 203 | 230 | 252 | 247 |
| OPM % | 21% | 21% | 20% | 19% | 14% | 18% | 22% | 22% | 22% | 21% | 20% | 21% | 20% |
| Other Income | 5 | 5 | 1 | 3 | 0 | 2 | 1 | 2 | 2 | 3 | 6 | 33 | -10 |
| Interest | 7 | 13 | 17 | 19 | 22 | 26 | 29 | 29 | 27 | 26 | 27 | 24 | 24 |
| Depreciation | 43 | 44 | 48 | 49 | 49 | 53 | 52 | 53 | 53 | 53 | 57 | 64 | 69 |
| Profit before tax | 166 | 190 | 167 | 164 | 65 | 136 | 170 | 176 | 181 | 128 | 153 | 198 | 145 |
| Tax % | 23% | 24% | 26% | 27% | 27% | 25% | 26% | 26% | 26% | 24% | 23% | 23% | 22% |
| Net Profit | 128 | 145 | 124 | 120 | 48 | 102 | 126 | 130 | 135 | 97 | 118 | 152 | 113 |
| EPS in Rs | 5.14 | 5.84 | 5.14 | 4.94 | 1.98 | 4.21 | 5.18 | 5.35 | 5.56 | 4.01 | 4.85 | 6.27 | 4.64 |
Last Updated: August 20, 2025, 10:10 am
Below is a detailed analysis of the quarterly data for Granules India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,210.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,197.00 Cr. (Mar 2025) to 1,210.00 Cr., marking an increase of 13.00 Cr..
- For Expenses, as of Jun 2025, the value is 963.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 945.00 Cr. (Mar 2025) to 963.00 Cr., marking an increase of 18.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 247.00 Cr.. The value appears to be declining and may need further review. It has decreased from 252.00 Cr. (Mar 2025) to 247.00 Cr., marking a decrease of 5.00 Cr..
- For OPM %, as of Jun 2025, the value is 20.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Mar 2025) to 20.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is -10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to -10.00 Cr., marking a decrease of 43.00 Cr..
- For Interest, as of Jun 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Depreciation, as of Jun 2025, the value is 69.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 64.00 Cr. (Mar 2025) to 69.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 145.00 Cr.. The value appears to be declining and may need further review. It has decreased from 198.00 Cr. (Mar 2025) to 145.00 Cr., marking a decrease of 53.00 Cr..
- For Tax %, as of Jun 2025, the value is 22.00%. The value appears to be improving (decreasing) as expected. It has decreased from 23.00% (Mar 2025) to 22.00%, marking a decrease of 1.00%.
- For Net Profit, as of Jun 2025, the value is 113.00 Cr.. The value appears to be declining and may need further review. It has decreased from 152.00 Cr. (Mar 2025) to 113.00 Cr., marking a decrease of 39.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.64. The value appears to be declining and may need further review. It has decreased from 6.27 (Mar 2025) to 4.64, marking a decrease of 1.63.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:16 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,084 | 1,292 | 1,357 | 1,411 | 1,685 | 2,279 | 2,599 | 3,238 | 3,765 | 4,512 | 4,506 | 4,482 | 4,512 |
| Expenses | 925 | 1,082 | 1,081 | 1,112 | 1,406 | 1,895 | 2,073 | 2,382 | 3,038 | 3,597 | 3,648 | 3,534 | 3,579 |
| Operating Profit | 159 | 210 | 276 | 299 | 278 | 384 | 526 | 856 | 727 | 915 | 858 | 948 | 933 |
| OPM % | 15% | 16% | 20% | 21% | 17% | 17% | 20% | 26% | 19% | 20% | 19% | 21% | 21% |
| Other Income | 4 | 3 | 5 | 35 | 27 | 75 | 90 | 26 | 13 | 12 | 2 | 41 | 32 |
| Interest | 20 | 32 | 37 | 32 | 33 | 28 | 27 | 26 | 23 | 56 | 106 | 103 | 100 |
| Depreciation | 30 | 53 | 58 | 72 | 76 | 105 | 137 | 151 | 159 | 184 | 207 | 226 | 241 |
| Profit before tax | 112 | 128 | 186 | 230 | 196 | 326 | 451 | 704 | 558 | 687 | 547 | 660 | 623 |
| Tax % | 33% | 29% | 33% | 28% | 32% | 27% | 26% | 22% | 26% | 25% | 26% | 24% | |
| Net Profit | 75 | 91 | 123 | 165 | 133 | 236 | 335 | 549 | 413 | 517 | 405 | 502 | 480 |
| EPS in Rs | 3.71 | 4.45 | 5.68 | 7.19 | 5.22 | 9.30 | 13.19 | 22.18 | 16.64 | 21.34 | 16.72 | 20.68 | 19.77 |
| Dividend Payout % | 9% | 11% | 11% | 13% | 19% | 11% | 8% | 7% | 9% | 7% | 9% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 21.33% | 35.16% | 34.15% | -19.39% | 77.44% | 41.95% | 63.88% | -24.77% | 25.18% | -21.66% | 23.95% |
| Change in YoY Net Profit Growth (%) | 0.00% | 13.83% | -1.02% | -53.54% | 96.84% | -35.49% | 21.93% | -88.65% | 49.95% | -46.85% | 45.61% |
Granules India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 12% |
| 3 Years: | 6% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| TTM: | -3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 8% |
| 3 Years: | 19% |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 17% |
| 3 Years: | 15% |
| Last Year: | 14% |
Last Updated: September 5, 2025, 5:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:18 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 20 | 22 | 23 | 25 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 24 |
| Reserves | 336 | 411 | 640 | 881 | 1,279 | 1,504 | 1,818 | 2,149 | 2,562 | 2,811 | 3,201 | 3,691 | 3,959 |
| Borrowings | 442 | 482 | 641 | 656 | 978 | 991 | 892 | 849 | 1,106 | 1,136 | 1,315 | 1,455 | 1,807 |
| Other Liabilities | 194 | 289 | 260 | 319 | 388 | 458 | 487 | 690 | 819 | 932 | 957 | 1,051 | 1,154 |
| Total Liabilities | 992 | 1,203 | 1,563 | 1,879 | 2,670 | 2,979 | 3,223 | 3,713 | 4,512 | 4,903 | 5,498 | 6,221 | 6,944 |
| Fixed Assets | 482 | 617 | 560 | 644 | 777 | 944 | 1,204 | 1,332 | 1,541 | 1,911 | 2,096 | 2,426 | 2,816 |
| CWIP | 125 | 62 | 77 | 267 | 515 | 496 | 294 | 239 | 356 | 239 | 272 | 440 | 702 |
| Investments | 0 | 0 | 70 | 108 | 157 | 210 | 19 | 19 | 20 | 21 | 22 | 22 | 1 |
| Other Assets | 385 | 524 | 856 | 859 | 1,222 | 1,328 | 1,706 | 2,123 | 2,594 | 2,732 | 3,109 | 3,333 | 3,425 |
| Total Assets | 992 | 1,203 | 1,563 | 1,879 | 2,670 | 2,979 | 3,223 | 3,713 | 4,512 | 4,903 | 5,498 | 6,221 | 6,944 |
Below is a detailed analysis of the balance sheet data for Granules India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,959.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,691.00 Cr. (Mar 2025) to 3,959.00 Cr., marking an increase of 268.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,807.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,455.00 Cr. (Mar 2025) to 1,807.00 Cr., marking an increase of 352.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,154.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,051.00 Cr. (Mar 2025) to 1,154.00 Cr., marking an increase of 103.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 6,944.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,221.00 Cr. (Mar 2025) to 6,944.00 Cr., marking an increase of 723.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,816.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,426.00 Cr. (Mar 2025) to 2,816.00 Cr., marking an increase of 390.00 Cr..
- For CWIP, as of Sep 2025, the value is 702.00 Cr.. The value appears strong and on an upward trend. It has increased from 440.00 Cr. (Mar 2025) to 702.00 Cr., marking an increase of 262.00 Cr..
- For Investments, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 22.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 21.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,425.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,333.00 Cr. (Mar 2025) to 3,425.00 Cr., marking an increase of 92.00 Cr..
- For Total Assets, as of Sep 2025, the value is 6,944.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,221.00 Cr. (Mar 2025) to 6,944.00 Cr., marking an increase of 723.00 Cr..
Notably, the Reserves (3,959.00 Cr.) exceed the Borrowings (1,807.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -283.00 | -272.00 | -365.00 | -357.00 | -700.00 | -607.00 | -366.00 | 7.00 | 726.00 | 914.00 | 857.00 | 947.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 37 | 39 | 101 | 108 | 136 | 108 | 93 | 86 | 90 | 77 | 80 | 77 |
| Inventory Days | 99 | 110 | 128 | 145 | 114 | 112 | 125 | 205 | 190 | 182 | 235 | 284 |
| Days Payable | 77 | 92 | 91 | 116 | 112 | 94 | 102 | 142 | 124 | 124 | 135 | 154 |
| Cash Conversion Cycle | 59 | 57 | 138 | 137 | 138 | 126 | 116 | 150 | 156 | 135 | 179 | 207 |
| Working Capital Days | 14 | 6 | 9 | -2 | 42 | 48 | 63 | 62 | 44 | 36 | 35 | 42 |
| ROCE % | 20% | 19% | 20% | 18% | 12% | 15% | 17% | 25% | 17% | 19% | 15% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Value Fund | 2,441,258 | 2.19 | 138.08 | N/A | N/A | N/A |
| Edelweiss Balanced Advantage Fund | 2,209,668 | 0.94 | 124.98 | N/A | N/A | N/A |
| Aditya Birla Sun Life Small Cap Fund | 1,106,670 | 1.22 | 62.59 | N/A | N/A | N/A |
| Tata Aggressive Hybrid Fund | 1,100,000 | 1.5 | 62.22 | N/A | N/A | N/A |
| Aditya Birla Sun Life Multi-Cap Fund | 1,038,748 | 0.87 | 58.75 | N/A | N/A | N/A |
| Tata Mid Cap Fund | 1,000,767 | 1.07 | 56.6 | N/A | N/A | N/A |
| Axis Multicap Fund | 787,153 | 0.49 | 44.52 | N/A | N/A | N/A |
| Tata Large Cap Fund | 533,136 | 1.08 | 30.15 | N/A | N/A | N/A |
| Axis Midcap Fund | 508,096 | 0.09 | 28.74 | N/A | N/A | N/A |
| Edelweiss Aggressive Hybrid Fund | 335,000 | 0.57 | 18.95 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 20.69 | 16.73 | 21.05 | 16.66 | 22.05 |
| Diluted EPS (Rs.) | 20.68 | 16.72 | 21.00 | 16.60 | 21.95 |
| Cash EPS (Rs.) | 29.98 | 25.28 | 28.97 | 23.04 | 28.30 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 153.19 | 133.08 | 117.13 | 104.32 | 87.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 153.19 | 133.08 | 117.13 | 104.32 | 87.75 |
| Revenue From Operations / Share (Rs.) | 184.78 | 185.93 | 186.41 | 151.81 | 130.72 |
| PBDIT / Share (Rs.) | 39.51 | 35.50 | 38.32 | 29.83 | 35.62 |
| PBIT / Share (Rs.) | 30.21 | 26.94 | 30.70 | 23.44 | 29.50 |
| PBT / Share (Rs.) | 27.22 | 22.58 | 28.39 | 22.50 | 28.44 |
| Net Profit / Share (Rs.) | 20.68 | 16.72 | 21.34 | 16.64 | 22.18 |
| NP After MI And SOA / Share (Rs.) | 20.68 | 16.72 | 21.34 | 16.64 | 22.18 |
| PBDIT Margin (%) | 21.37 | 19.09 | 20.55 | 19.65 | 27.24 |
| PBIT Margin (%) | 16.34 | 14.49 | 16.46 | 15.43 | 22.56 |
| PBT Margin (%) | 14.73 | 12.14 | 15.23 | 14.82 | 21.75 |
| Net Profit Margin (%) | 11.19 | 8.99 | 11.44 | 10.96 | 16.97 |
| NP After MI And SOA Margin (%) | 11.19 | 8.99 | 11.44 | 10.96 | 16.97 |
| Return on Networth / Equity (%) | 13.49 | 12.56 | 18.22 | 15.95 | 25.28 |
| Return on Capital Employeed (%) | 17.24 | 18.99 | 24.04 | 20.24 | 28.76 |
| Return On Assets (%) | 8.02 | 7.34 | 10.53 | 9.14 | 14.79 |
| Long Term Debt / Equity (X) | 0.08 | 0.02 | 0.05 | 0.09 | 0.15 |
| Total Debt / Equity (X) | 0.34 | 0.37 | 0.37 | 0.42 | 0.38 |
| Asset Turnover Ratio (%) | 0.76 | 0.86 | 0.87 | 0.80 | 0.90 |
| Current Ratio (X) | 1.56 | 1.40 | 1.42 | 1.53 | 1.70 |
| Quick Ratio (X) | 0.88 | 0.77 | 0.78 | 0.92 | 1.04 |
| Inventory Turnover Ratio (X) | 3.39 | 1.80 | 2.67 | 2.72 | 3.34 |
| Dividend Payout Ratio (NP) (%) | 7.24 | 8.95 | 3.60 | 9.00 | 4.50 |
| Dividend Payout Ratio (CP) (%) | 5.00 | 5.92 | 2.65 | 6.50 | 3.53 |
| Earning Retention Ratio (%) | 92.76 | 91.05 | 96.40 | 91.00 | 95.50 |
| Cash Earning Retention Ratio (%) | 95.00 | 94.08 | 97.35 | 93.50 | 96.47 |
| Interest Coverage Ratio (X) | 9.28 | 8.13 | 16.58 | 31.87 | 33.56 |
| Interest Coverage Ratio (Post Tax) (X) | 5.56 | 4.83 | 10.24 | 18.78 | 21.90 |
| Enterprise Value (Cr.) | 12503.53 | 11257.54 | 7783.15 | 8280.28 | 8079.39 |
| EV / Net Operating Revenue (X) | 2.79 | 2.50 | 1.73 | 2.20 | 2.50 |
| EV / EBITDA (X) | 13.05 | 13.08 | 8.39 | 11.19 | 9.16 |
| MarketCap / Net Operating Revenue (X) | 2.64 | 2.31 | 1.56 | 2.02 | 2.32 |
| Retention Ratios (%) | 92.75 | 91.04 | 96.39 | 90.99 | 95.49 |
| Price / BV (X) | 3.18 | 3.23 | 2.48 | 2.94 | 3.46 |
| Price / Net Operating Revenue (X) | 2.64 | 2.31 | 1.56 | 2.02 | 2.32 |
| EarningsYield | 0.04 | 0.03 | 0.07 | 0.05 | 0.07 |
After reviewing the key financial ratios for Granules India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 20.69. This value is within the healthy range. It has increased from 16.73 (Mar 24) to 20.69, marking an increase of 3.96.
- For Diluted EPS (Rs.), as of Mar 25, the value is 20.68. This value is within the healthy range. It has increased from 16.72 (Mar 24) to 20.68, marking an increase of 3.96.
- For Cash EPS (Rs.), as of Mar 25, the value is 29.98. This value is within the healthy range. It has increased from 25.28 (Mar 24) to 29.98, marking an increase of 4.70.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 153.19. It has increased from 133.08 (Mar 24) to 153.19, marking an increase of 20.11.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 153.19. It has increased from 133.08 (Mar 24) to 153.19, marking an increase of 20.11.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 184.78. It has decreased from 185.93 (Mar 24) to 184.78, marking a decrease of 1.15.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 39.51. This value is within the healthy range. It has increased from 35.50 (Mar 24) to 39.51, marking an increase of 4.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is 30.21. This value is within the healthy range. It has increased from 26.94 (Mar 24) to 30.21, marking an increase of 3.27.
- For PBT / Share (Rs.), as of Mar 25, the value is 27.22. This value is within the healthy range. It has increased from 22.58 (Mar 24) to 27.22, marking an increase of 4.64.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 20.68. This value is within the healthy range. It has increased from 16.72 (Mar 24) to 20.68, marking an increase of 3.96.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 20.68. This value is within the healthy range. It has increased from 16.72 (Mar 24) to 20.68, marking an increase of 3.96.
- For PBDIT Margin (%), as of Mar 25, the value is 21.37. This value is within the healthy range. It has increased from 19.09 (Mar 24) to 21.37, marking an increase of 2.28.
- For PBIT Margin (%), as of Mar 25, the value is 16.34. This value is within the healthy range. It has increased from 14.49 (Mar 24) to 16.34, marking an increase of 1.85.
- For PBT Margin (%), as of Mar 25, the value is 14.73. This value is within the healthy range. It has increased from 12.14 (Mar 24) to 14.73, marking an increase of 2.59.
- For Net Profit Margin (%), as of Mar 25, the value is 11.19. This value exceeds the healthy maximum of 10. It has increased from 8.99 (Mar 24) to 11.19, marking an increase of 2.20.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.19. This value is within the healthy range. It has increased from 8.99 (Mar 24) to 11.19, marking an increase of 2.20.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.49. This value is below the healthy minimum of 15. It has increased from 12.56 (Mar 24) to 13.49, marking an increase of 0.93.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.24. This value is within the healthy range. It has decreased from 18.99 (Mar 24) to 17.24, marking a decrease of 1.75.
- For Return On Assets (%), as of Mar 25, the value is 8.02. This value is within the healthy range. It has increased from 7.34 (Mar 24) to 8.02, marking an increase of 0.68.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has increased from 0.02 (Mar 24) to 0.08, marking an increase of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.34. This value is within the healthy range. It has decreased from 0.37 (Mar 24) to 0.34, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 0.86 (Mar 24) to 0.76, marking a decrease of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 1.56, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has increased from 0.77 (Mar 24) to 0.88, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.39. This value is below the healthy minimum of 4. It has increased from 1.80 (Mar 24) to 3.39, marking an increase of 1.59.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.24. This value is below the healthy minimum of 20. It has decreased from 8.95 (Mar 24) to 7.24, marking a decrease of 1.71.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.00. This value is below the healthy minimum of 20. It has decreased from 5.92 (Mar 24) to 5.00, marking a decrease of 0.92.
- For Earning Retention Ratio (%), as of Mar 25, the value is 92.76. This value exceeds the healthy maximum of 70. It has increased from 91.05 (Mar 24) to 92.76, marking an increase of 1.71.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.00. This value exceeds the healthy maximum of 70. It has increased from 94.08 (Mar 24) to 95.00, marking an increase of 0.92.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 9.28. This value is within the healthy range. It has increased from 8.13 (Mar 24) to 9.28, marking an increase of 1.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.56. This value is within the healthy range. It has increased from 4.83 (Mar 24) to 5.56, marking an increase of 0.73.
- For Enterprise Value (Cr.), as of Mar 25, the value is 12,503.53. It has increased from 11,257.54 (Mar 24) to 12,503.53, marking an increase of 1,245.99.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.79. This value is within the healthy range. It has increased from 2.50 (Mar 24) to 2.79, marking an increase of 0.29.
- For EV / EBITDA (X), as of Mar 25, the value is 13.05. This value is within the healthy range. It has decreased from 13.08 (Mar 24) to 13.05, marking a decrease of 0.03.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.64. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 2.64, marking an increase of 0.33.
- For Retention Ratios (%), as of Mar 25, the value is 92.75. This value exceeds the healthy maximum of 70. It has increased from 91.04 (Mar 24) to 92.75, marking an increase of 1.71.
- For Price / BV (X), as of Mar 25, the value is 3.18. This value exceeds the healthy maximum of 3. It has decreased from 3.23 (Mar 24) to 3.18, marking a decrease of 0.05.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.64. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 2.64, marking an increase of 0.33.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Granules India Ltd:
- Net Profit Margin: 11.19%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.24% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.49% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.56
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.88
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.8 (Industry average Stock P/E: 42.62)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.34
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.19%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 15th Floor, Granules Tower, Botanical Garden Road, Hyderabad Telangana 500084 | investorrelations@granulesindia.com http://www.granulesindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Krishna Prasad Chigurupati | Chairman & Managing Director |
| Dr. K V S Ram Rao | Joint Managing Director & CEO |
| Mr. Harsha Chigurupati | Non Ind.& Exe.Director |
| Mrs. Uma Devi Chigurupati | Non Ind.& Exe.Director |
| Mr. Kolli Basava Sankar Rao | Non Exe.Non Ind.Director |
| Dr. Saumen Chakraborty | Ind. Non-Executive Director |
| Mrs. Sucharita Rao Palepu | Ind. Non-Executive Director |
| Dr. Sethurathnam Ravi | Ind. Non-Executive Director |
| Mr. Arun Sawhney | Ind. Non-Executive Director |
| Mr. Kapil Kumar Mehan | Ind. Non-Executive Director |
| Mrs. Priyanka Chigurupati | Non Ind.& Exe.Director |
| Mr. Rajiv Pritidas Kakodkar | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Granules India Ltd?
Granules India Ltd's intrinsic value (as of 12 December 2025) is 490.07 which is 13.26% lower the current market price of 565.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 13,705 Cr. market cap, FY2025-2026 high/low of 621/412, reserves of ₹3,959 Cr, and liabilities of 6,944 Cr.
What is the Market Cap of Granules India Ltd?
The Market Cap of Granules India Ltd is 13,705 Cr..
What is the current Stock Price of Granules India Ltd as on 12 December 2025?
The current stock price of Granules India Ltd as on 12 December 2025 is 565.
What is the High / Low of Granules India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Granules India Ltd stocks is 621/412.
What is the Stock P/E of Granules India Ltd?
The Stock P/E of Granules India Ltd is 26.8.
What is the Book Value of Granules India Ltd?
The Book Value of Granules India Ltd is 164.
What is the Dividend Yield of Granules India Ltd?
The Dividend Yield of Granules India Ltd is 0.27 %.
What is the ROCE of Granules India Ltd?
The ROCE of Granules India Ltd is 15.1 %.
What is the ROE of Granules India Ltd?
The ROE of Granules India Ltd is 13.9 %.
What is the Face Value of Granules India Ltd?
The Face Value of Granules India Ltd is 1.00.